These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 31576013)

  • 1. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
    Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
    Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DKK1 suppresses WWP2 to enhance bortezomib resistance in multiple myeloma via regulating GLI2 ubiquitination.
    Zhang Q; Gong W; Wu H; Wang J; Jin Q; Lin C; Xu S; Bao W; Wang Y; Wu J; Feng S; Zhao C; Chen B; Liu Z
    Carcinogenesis; 2021 Oct; 42(10):1223-1231. PubMed ID: 34546340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Hedgehog signaling pathway promotes chemotherapy resistance via multidrug resistance protein 1 in ovarian cancer.
    Zhang H; Hu L; Cheng M; Wang Q; Hu X; Chen Q
    Oncol Rep; 2020 Dec; 44(6):2610-2620. PubMed ID: 33125122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists.
    Liu F; Jiang W; Sui Y; Meng W; Hou L; Li T; Li M; Zhang L; Mo J; Wang J; Zhao Y; Zhang L; Ma J; Tang Y
    Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12986-12995. PubMed ID: 31182587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
    Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
    Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
    Bennett MK; Li M; Tea MN; Pitman MR; Toubia J; Wang PP; Anderson D; Creek DJ; Orlowski RZ; Gliddon BL; Powell JA; Wallington-Beddoe CT; Pitson SM
    Neoplasia; 2022 Jan; 24(1):1-11. PubMed ID: 34826777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deacetylation induced nuclear condensation of HP1γ promotes multiple myeloma drug resistance.
    Li X; Wang S; Xie Y; Jiang H; Guo J; Wang Y; Peng Z; Hu M; Wang M; Wang J; Li Q; Wang Y; Liu Z
    Nat Commun; 2023 Mar; 14(1):1290. PubMed ID: 36894562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling.
    Tang B; Xu A; Xu J; Huang H; Chen L; Su Y; Zhang L; Li J; Fan F; Deng J; Tang L; Sun C; Hu Y
    Int J Cancer; 2018 Jan; 142(1):109-120. PubMed ID: 28905994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostaglandin E1 Inhibits
    Wu F; Zhang C; Zhao C; Wu H; Teng Z; Jiang T; Wang Y
    Cancer Res; 2020 Jul; 80(13):2818-2832. PubMed ID: 32371475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
    Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
    Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the cross-talk between the hedgehog and NF-κB signaling pathways in multiple myeloma.
    Cai K; Na W; Guo M; Xu R; Wang X; Qin Y; Wu Y; Jiang J; Huang H
    Leuk Lymphoma; 2019 Mar; 60(3):772-781. PubMed ID: 30644322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.
    Zheng Z; Fan S; Zheng J; Huang W; Gasparetto C; Chao NJ; Hu J; Kang Y
    J Hematol Oncol; 2018 Feb; 11(1):29. PubMed ID: 29482577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.
    Kikuchi J; Yamada S; Koyama D; Wada T; Nobuyoshi M; Izumi T; Akutsu M; Kano Y; Furukawa Y
    J Biol Chem; 2013 Aug; 288(35):25593-25602. PubMed ID: 23878197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
    Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
    Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
    [No Abstract]   [Full Text] [Related]  

  • 16. Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance.
    Ge M; Qiao Z; Kong Y; Liang H; Sun Y; Lu H; Xu Z; Liu H
    Br J Cancer; 2021 Feb; 124(4):770-776. PubMed ID: 33250513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
    Chong PSY; Zhou J; Lim JSL; Hee YT; Chooi JY; Chung TH; Tan ZT; Zeng Q; Waller DD; Sebag M; Chng WJ
    Cancer Res; 2019 Sep; 79(18):4679-4688. PubMed ID: 31337650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.
    Savvidou I; Khong T; Cuddihy A; McLean C; Horrigan S; Spencer A
    Mol Cancer Ther; 2017 Sep; 16(9):1765-1778. PubMed ID: 28500235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
    Jagannathan S; Vad N; Vallabhapurapu S; Vallabhapurapu S; Anderson KC; Driscoll JJ
    Leukemia; 2015 Mar; 29(3):727-38. PubMed ID: 25234165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive feedback of SuFu negating protein 1 on Hedgehog signaling promotes colorectal tumor growth.
    Yan Z; Cheng M; Hu G; Wang Y; Zeng S; Huang A; Xu L; Liu Y; Shi C; Deng L; Lu Q; Rao H; Lu H; Chen YG; Luo S
    Cell Death Dis; 2021 Feb; 12(2):199. PubMed ID: 33608498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.